APOC3 and metabolic syndrome: Emerging agents such as ANGPTL3 and apoC-III inhibitors, as well as novel therapies like inclisiran and icosapent ethyl, offer promising avenues for further reducing cardiovascular risk in patients with persistent dyslipidemia after ACS.